Make us your home page
Instagram

Today’s top headlines delivered to you daily.

(View our Privacy Policy)

Three women blinded by unapproved stem cell 'treatment' at Florida clinic

Age-related macular degeneration is the leading cause of vision loss in people older than 75 in the United States. While researchers are making "tremendous" progress using stem cells to treat the disease, the field requires careful study with meticulously designed trials, the authors of the paper said. The FDA has approved only a few stem-cell therapies, mostly for blood disorders. [Karen Bleier | AFP | Getty Images]

Age-related macular degeneration is the leading cause of vision loss in people older than 75 in the United States. While researchers are making "tremendous" progress using stem cells to treat the disease, the field requires careful study with meticulously designed trials, the authors of the paper said. The FDA has approved only a few stem-cell therapies, mostly for blood disorders. [Karen Bleier | AFP | Getty Images]

Three women with macular degeneration became permanently blind after undergoing an unproven stem-cell treatment touted as a clinical trial at a South Florida clinic. Medical experts said the episode raises questions about whether the government and doctors are doing enough to protect patients from the dangers of unapproved therapies.

The episode, described Wednesday in an article in the New England Journal of Medicine, represents one of the most egregious examples of patient injury involving a stem-cell clinic. These facilities have sprung up by the hundreds across the country over the past several years. Many offer supposed experimental treatments for ailments ranging from hip problems to autism to ALS.

Of special concern, said Jeffrey Goldberg, professor of ophthalmology at the Stanford University School of Medicine and one of the authors of the report, was the clinic's ability to list its study on ClinicalTrials.gov, a comprehensive database of clinical trials run by the National Institutes of Health. At least one of the patients — and maybe more — believed that she was taking part in a government-sanctioned study, he said.

Goldberg called the incident a "wake-up call across the spectrum" — for patients, physicians and government regulators. "Surely," he said, "it's an opportunity for the FDA to increase patient safety for these unapproved clinical trials."

RELATED COVERAGE: Tampa stem cell clinic is long on promises, not evidence

Thomas Albini, a University of Miami ophthalmologist and another one of the authors, said that he and his colleagues at the Bascom Palmer Eye Institute had treated two of the patients for severe complications in 2015, shortly after they had undergone the stem-cell procedures at a clinic in Sunrise. The severe complications included detached retinas, hemorrhages and vision loss.

"It's a disaster," Albini said, noting that the patients, before the stem-cell treatments, had only moderate vision loss. "Buyer beware: These stem-cell clinics that function in this very unregulated way are doing procedures that are not approved . . . and they can be quite dangerous."

The NEJM article did not identify the clinic or the patients, but its listing on the ClinicalTrials.gov website shows the sponsor as Bioheart Inc., also known as U.S. Stem Cell Inc., and says that the study was "withdrawn" before patients were enrolled. The clinic still has other stem-cell studies listed on the site, including for chronic obstructive pulmonary disease and degenerative disc disease.

RELATED COVERAGE: Desperate families turn to unproven stem cell treatment

Repeated calls to U.S. Stem Cell and to Kirstin Comella, who is listed as the chief scientific officer, have not been returned. In a NPR story last year, Comella said that two of the clinic's patients had suffered detached retinas following treatments, prompting the clinic to stop doing eye procedures.

According to Florida court filings, two of the patients involved, ages 72 and 78 at the time, sued the clinic and some individuals involved in the procedures. Their attorney, Andrew Yaffa of Coral Gables, said that the case "was resolved to the mutual satisfaction of the parties" but that neither he nor his clients could comment beyond that. The third patient was an 88-year-old Oklahoma resident who sought medical help a week after the stem-cell procedure at the Dean McGee Eye Institute in Oklahoma City.

Albini said the eye damage could have been the result of contamination during preparation of the stem cells. He also said it was possible that the stem cells could have changed into cells that are associated with scarring. Even if the solution had been prepared correctly, he said, there's no evidence that it could have helped restore the patients' vision.

Albini said the three patients paid $5,000 each for the stem-cell procedure, which involved conducting mini-liposuction procedures to remove fat from the abdominal area, isolating the stem cells from the fat and injecting those cells directly into eyes. Charging the patients was a "red flag," he said, that this was not a traditional clinical trial. A second was treating both eyes at the same time, rather than seeing how one eye responded before treating the other.

Age-related macular degeneration is the leading cause of vision loss in people older than 75 in the United States. While researchers are making "tremendous" progress using stem cells to treat the disease, the field requires careful study with meticulously designed trials, the authors of the paper said. The FDA has approved only a few stem-cell therapies, mostly for blood disorders.

The proliferation of stem-cell clinics — there are more than 570 of them, according to a study published last year — has ignited a fierce debate among physicians, patients and scientists about how they should be regulated. FDA rules allow the use of patients' own stem cells for treatments, without agency approval, but only if the procedures meet stringent conditions. The stem cells, for example, cannot be more than "minimally manipulated" and must be intended for the original function. That would not typically include using stem cells from fat to repair eye cells.

Albini said that the FDA had started an investigation into the case but a spokeswoman said the agency does not discuss potential or ongoing investigations. She added that consumers are encouraged to contact the FDA and state authorities to report any potentially illegal or harmful activity related to stem-cell-based products. The FDA has issued several drafts of guidance for the stem-cell industry to try to outline its thinking on the matter, but the documents have not been finalized, and many clinic operators oppose FDA regulation.

Paul Knoepfler, a stem-cell scientist at the University of California at Davis who is a frequent critic of the clinics, said he didn't understand why the FDA and the NIH have not moved more aggressively to ensure patient safety.

"It's puzzling and concerning," he said. He said that allowing the clinics to list their trials on ClinicalTrials.gov is "almost like a form of advertising for products that don't have FDA approval. That's really problematic."

In a statement, the NIH said that the information on ClinicalTrials.gov is provided by study sponsors and that posting on the site doesn't reflect endorsement by the NIH, which doesn't independently verify the scientific validity of the trial. It also said that every study includes links to an NIH disclaimer. "However, we agree that such caveats need to be clearer to all users and we will be adding a more prominent disclaimer in the future."

Three women blinded by unapproved stem cell 'treatment' at Florida clinic 03/16/17 [Last modified: Thursday, March 16, 2017 8:56am]
Photo reprints | Article reprints

© 2017 Tampa Bay Times

    

Join the discussion: Click to view comments, add yours

Loading...
  1. Photo of the Day for August 17, 2017 - 'Keeping a watchful eye'

    Human Interest

    Today's Photo of the Day comes from George Capaz of Wesley Chapel, FL. The photo was taken at a small roadside lake at Bruce B. Downs Blvd and Cross Creek Blvd.

  2. Jerseys worn by Tim Tebow fans commemorate the various phases of his athletic career

    Minors

    His fans have come out in droves during Tim Tebow Week in Tampa Bay, more than doubling the average in Clearwater and Tampa Bay. And they've come adorned with jerseys commemorating the many phases of Tebow's …

    Charles Bottoms, right, with his wife, Annie, wore the Tim Tebow Broncos jersey to Steinbrenner Field "only because I didn't want to wear my good (signed Gators) Tebow one." [RYAN ROMANO | Times]
  3. Security threat leads Florida to cancel prison visitation

    Crime

    TALLAHASSEE — Prison officials in Florida cited a security threat in canceling visitation at all of its 149 facilities.

  4. Steve Bannon says rivals 'wetting themselves,' calls supremacists 'clowns,' seems to contradict Trump on North Korea

    National

    Stephen K. Bannon, the White House chief strategist, seemed to take issue with President Donald Trump on North Korea, attacked white supremacists as "clowns" and "losers" and described his efforts against administration rivals in an unusual interview Wednesday with the American Prospect, a progressive magazine.

    White House chief strategist Steve Bannon steps off Air Force One at Andrews Air Force Base, Md., in April. In an unusual interview Wednesday with The American Prospect, a progressive magazine, Bannon attacked white supremacists as "clowns" and "losers" and described his efforts against administration rivals saying "They're wetting themselves." [Associated Press]
  5. Why are so few Tampa Bay houses for sale? They're being rented

    Real Estate

    Oreste Mesa Jr. owns a modest 40-year-old house in West Tampa just off MacDill Avenue. It's an area where many homeowners are hearing the siren song of builders and cashing out while the market is strong.

    Attorney David Eaton poses in front of his rental home at 899 72nd Ave. North. in St. Petersburg. He's among a growing number of property owners who see more value in renting out unused homes than selling them. 
[SCOTT KEELER   |   Times]